Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Viral vectored vaccines combine a safe virus with a pathogen protein to protect against a specific disease.

They are very good at inducing T cell responses, which is crucial for protection against viral infections and diseases such as malaria. Viral vectored vaccines have the potential to drastically improve public health.

Q: What is a viral vectored vaccine?

SG: Most people will be familiar with live attenuated viral vaccines where we use a weakened form of a virus that would normally cause the disease, to make a vaccine against that disease. For example measles, mumps and rubella vaccines are an example of mixing together three live-attenuated vaccines to make vaccines against those three diseases. What we're doing now is taking different viruses and making them really safe to use in people but then adding in parts of pathogens so we can make new vaccines against those other pathogens. For example we could take a virus that would normally cause a cold and we could add in parts of the malaria parasite to make a vaccine against malaria. Or we could take a safe version of the vaccine that we use against small pox and add in parts of the flu virus to make a new flu vaccine.

Q: Why should we use these vaccines?

SG: What these viral vectored vaccines are really good at doing is inducing T cell responses in the person that we vaccinate. So a lot of the vaccines that we use are protein and adjuvant vaccines and they're very good at inducing antibodies against the protein that's used in the vaccine and that's helpful against protecting against some diseases. But for other diseases we need to engage the other major part of the immune system and that's the T cell response. Viral vectored vaccines are really good at doing that and we need that for some particular diseases such as malaria and some viral diseases. They're also useful for vaccinating against cancer. Viral vectored vaccines can also induce antibodies so we can get both an antibody and a T cell response at the same time.

Q: How far has this research progressed?

SG: Within the Jenner Institute over the last few years we've done about 50 different clinical trials of viral vectored vaccines for different diseases mainly in malaria but also against tuberculosis, HIV, influenza, hepatitis C so we've come a long way in understanding how to use these viral vectored vaccines in people.

Q: What are the most important lines of research that have developed in the past 5 or 10 years?

SG: Going back to about the last 50 years, we were using vaccines that were really effective but often had some nasty side effects; for example the small-pox vaccine gave people a very unpleasant scar and could have some very serious side effects in some cases. So there was a big emphasis on improving vaccine safety. Unfortunately when we developed safer vaccines we ended up with some vaccines that were less effective than we could have had before. In the last 5 or 10 years we have been concentrating on making vaccines that are extremely safe but also have a high-level of efficacy and we are able to do that with these viral vectored vaccines. The compromise seems to be that we probably have to give more than one injection but the pay-off is that we get a very safe and very effective vaccine and we can use the technology to make vaccines against lots of different diseases. We've also become much better at understanding how T cells can protect us against disease and how to induce them by vaccination and how to measure if they're doing their job.

Q: Why does your line of research matter, why should we put money into it?

SG: We still need a lot more vaccines that we can use to vaccinate against diseases like malaria and HIV where we don't have a vaccine at all. For other diseases like tuberculosis and influenza we do have vaccines against but they're not particularly effective, especially in older people and we need to do better. If we can use viral vectored vaccines to make new vaccines that work in a different way we can really improve public health.

Q: How does your research fit into Translational Medicine within the department?

SG: Our research is very translational because a lot of it involves doing clinical trials of our new vaccines in volunteers. We have a clinical bio-manufacturing facility that can make the batches of vaccines we need for clinical trials in carefully controlled conditions and we also have a pre-clinical viral vectored core-facility that makes us lots of small batches of vaccines throughout the early stages of our research. We can also offer that service to other researchers that want to collaborate with us. Information about that is on the Jenner Institute website.

Sarah Gilbert

Vaccine Development

Professor Sarah Gilbert has been making and testing vaccines designed to induce T cell responses for ten years, chiefly using antigens from malaria and influenza. Based at the Jenner Institute, several of the vaccines developed in Professor Gilbert's laboratory have progressed into Clinical Trials.

More podcasts related to Epidemics & Vaccines

Richard Antrobus: Universal Flu Vaccine

A Universal Flu Vaccine would protect against a wide range of strains of the virus. Universal vaccines target the parts of the virus that stay relatively stable and are the same between different strains of flu. The ultimate goal is to produce a vaccine that will eventually replace the normal seasonal flu jab.

Jan Rehwinkel: How the innate immune system detects flu virus

The first arm of our immune response is triggered by the detection of the presence of the virus. RIG-I protein is an intracellular receptor that detects the presence of viral genomic information. A better understanding of these mechanisms might help us develop better vaccination strategies.

Peter Simmonds: Evolution and pathogenicity of viruses

RNA viruses are major pathogens that represent the majority of new viruses emerging over time. They are particularly good at evading the host's response to infection. A better understanding of the interaction between virus and host can lead to a better control of viral infections. Recent discoveries on viral genome composition and structure might allow us to manipulate this interaction and generate new, safer vaccines.

Susanna Dunachie: Tropical Immunology

Melioidosis is a neglected tropical disease, and a major infectious killer in South East Asia. Melioidosis particularly affects people with diabetes. Professor Dunachie studies how the patients' own immune system fight the disease, with the aim of designing a vaccine that could stop people getting sick and dying.

Ebola - Donning and Doffing PPE

The Ebola outbreak in West Africa has rapidly become the deadliest since the discovery of the virus. Was the British Government’s response appropriate? What are the risks to us? And what do we really know about this deadly disease?

Sergi Padilla-Parra: Virus entry

Novel light microscopy techniques allow us to track single viruses. From a virus centric approach, we can now study interactions between the host and the virus. In the case of HIV, we could demonstrate that the virus might enter the cell through endocytosis. A better understanding of virus-cell interactions will ultimately help us test and develop new drugs and vaccines.

David Stuart: Structural biology and vaccines

The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.

Kay Grunewald: Structural cell biology of virus infection

Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.

Paul Klenerman: Viruses, how to be the perfect host

When infected by hepatitis C virus, we either clear the virus or suffer from long term infection that leads to liver damage. The critical stage happens during the first few weeks of infections. Improving the immune response against the virus could be used to protect as well as cure people from hepatitis C.

Ellie Barnes: Hepatitis C vaccine

Inducing an antibody reaction to Hepatitis C does not work as it does in other vaccines as the antibodies target the outer surface of the Hepatitis C virus, which is very variable. Therefore efforts are being made to develop a vaccine which induces the T cell arm of the immune response, targeting the virus more effectively.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.